Other News To Note
• Algeta ASA, of Oslo, Norway, said partner Bayer AG, of Leverkusen, Germany, submitted a marketing authorization application to the European Medicines Agency for Alpharadin (radium-223 dichloride) for the treatment of castration-resistant prostate cancer patients with bone metastases. The submission triggers a €50 million (US$65.7 million) milestone payment under the firms' 2009 agreement, and it is based on positive data from the Phase III ALSYMPCA study, in which Alpharadin significantly increased overall survival by 44 percent.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST